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ACE-I = angiotensin-
converting enzyme inhibitor
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BB = beta-adrenergic
receptor blocking agent
CI = conﬁdence interval
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ejection fraction
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1586Mineralocorticoid receptor antag-
onists (MRAs) added to standard
therapy including an angioten-
sin converting enzyme inhibitor
(ACE-I) or angiotensin recep-
tor blocker (ARB) and a beta-
adrenergic receptor blocking
agent (BB) reducemortality aswell
as hospitalization for heart failure
(HF) in patients with a reduced
left ventricular ejection fraction
(HF-REF), irrespective of the
severity of symptoms (1,2), and in
patients with reduced left ven-
tricular ejection fraction and
symptoms of HF after myocardial
infarction (3). Mineralocorticoid
receptor antagonists, therefore,
have a pivotal place in the ma-
nagement of HF-REF (4) but, in
comparison with ACE-I (or
ARBs) andBBs, their use remains
suboptimal (5). The reluctance of
many clinicians to use a MRA in
patients with HF-REF mayin part be due to the belief that the large clinical trials, such as
RALES (Randomized Aldactone Evaluation Study) (1),
EPHESUS (Eplerenone Post-AcuteMyocardial Infarction
Heart Failure Efﬁcacy and Survival Study.) (3), and
EMPHASIS-HF (Eplerenone in Mild Patients Hospital-
ization And SurvIval Study in Heart Failure) (2), largely
excluded high-risk patients, particularly those susceptible
to hyperkalemia, worsening renal function (WRF), or both.
See page 1594
The aim of this analysis was to evaluate the safety and
efﬁcacy of the MRA eplerenone (25 to 50 mg/day) in pre-
speciﬁed high-risk subgroups of this type, namely patients
age 75 years, with diabetes mellitus, chronic kidney
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3; revised manuscript received April 13, 2013,[eGFR] <60 ml/min/1.73 m2), and systolic blood pressure
(SBP) < median (123 mm Hg).
Methods
The design (6) and results (2) of the EMPHASIS-HF study
have been published.
Patient selection. Patients included were at least 55 years
of age; were in New York Heart Association functional class
II; had a left ventricular ejection fraction <30% (or if
between 30% and 35%, the QRS duration had to be >130
ms); were treated with the recommended or maximally
tolerated dose of an ACE-I or an ARB and a BB (unless
contraindicated); and had been hospitalized for a cardiovas-
cular reason within the past 6 months (or had a B-type
natriuretic peptide level >250 pg/ml or N-terminal pro–B-
type natriuretic peptide >500 pg/ml in males and 750 pg/ml
for females).
Patients with an eGFR <30 ml/min/1.73 m2, need for
a potassium sparring diuretic, or any other signiﬁcant comorbid
condition was excluded.
All trial endpoints, including hospitalization for WRF
and for hyperkalemia were pre-speciﬁed and adjudicated by
an independent Critical Event Committee. Each center’s
Ethics Committee approved the trial and all patients
provided written informed consent.
Study procedure. Eplerenone or matching placebo was
started at a dose of 25 mg once daily (or if the eGFR was
30 to 49 ml/min/1.73 m2, at a dose of 25 mg every other
day) and increased to 50 mg once daily at 4 weeks,
provided the serum potassium was no more than 5.0
mmol/l (or if the eGFR was 30 to 49 ml/min/1.73 m2 at
baseline to 25 mg daily). Thereafter, the serum potassium
was measured every 4 months and investigators were
instructed to reduce the dose of the study drug if the serum
potassium was 5.5 to 5.9 mmol/l and to withhold the study
drug if the serum potassium was 6.0 mmol/l or more.
Serum potassium was checked within 72 h of stopping
study drug and restarted only if the serum potassium
was <5.0 mmol/l. Serum potassium was measured at
screening visit, Week 1, Week 4, every 4 months from
Month 5 to Month 37, and every 6 months starting at
Month 42 until the patient’s ﬁnal visit.
High-risk subgroups. The pre-speciﬁed high-risk sub-
groups were patients 75 years of age, those with diabetes
mellitus, CKD (i.e., an eGFR <60 ml/min/1.73 m2), and
subjects with an SBP <123 mm Hg (median) at baseline.
Study outcomes. The pre-speciﬁed safety outcomes in-
cluded serum potassium >5.5, >6.0, and <3.5 mmol/l;
hyperkalemia leading to study drug discontinuation; hospi-
talization for hyperkalemia and hospitalization for WRF;
change in eGFR; and the primary efﬁcacy outcome
(hospitalization for HF or death from cardiovascular causes)
were also reported.
Statistical analysis. The criteria for high-risk subgroups
were pre-speciﬁed in the statistical analysis plan. The
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1587following data are summarized by study treatment for each
of the high-risk subgroups:
1. Demographics, medical history, and relevant baseline
laboratory measurements and medications (summa-
rized using descriptive statistics).
2. Hospitalizations for hyperkalemia and for WRF were
analyzed using Cox proportional hazards models. The
incidence of serum potassium above or below the pre-
speciﬁed thresholds during the study were compared
using Fisher exact test. Change in eGFR between
baseline and the ﬁnal visit was analyzed using an
analysis of covariance model with baseline eGFR as
a covariate. We also examined for interactions
between baseline subgroup and the effect of treatment
on potassium and eGFR using the Zelen’s test and the
analysis of covariance model including the interaction
term, respectively.
The adverse event data and study medication data
including percent of subjects on highest dose (50 mg QD)
and mean dose at Month 5 visit, and subject discontinuation
are also summarized. Statistical comparisons between
treatment groups were performed using 2-sample t tests for
mean dose at Month 5 visit, and Fisher exact test for study
discontinuation due to adverse events. The BP change from
baseline is also presented by baseline SBP < median and 
median subgroups.Table 1 Baseline Characteristics
Characteristics
EMPHASIS-HF Study Population Age 75 yrs
Eplerenone
Group
(n ¼ 1,364)
Placebo
Group
(n ¼ 1,373)
Eplerenone
Group
(n ¼ 330)
Age, yrs 68.7  7.7 68.6  7.6 79.1  3.5
Female 309 (22.7) 301 (21.9) 78 (23.6)
Systolic blood pressure, mm Hg 124  17 124  17 127.07  17.1
Diastolic blood pressure, mm Hg 75  10 75  10 73.67  10.5
Left ventricular ejection fraction, % 26.2  4.6 26.1  4.7 26.72  4.3
Hospitalization for heart failure 714 (52.3) 726 (52.9) 169 (51.2)
Hypertension 910 (66.7) 909 (66.2) 250 (75.8)
Myocardial infarction 686 (50.3) 695 (50.6) 188 (57.0)
Diabetes mellitus 459 (33.7) 400 (29.1) 97 (29.4)
Serum creatinine, mg/dl 1.14  0.30 1.16  0.31 1.22  0.3
eGFR, ml/min/1.73 m2 of
body surface area
71.2  21.9 70.4  21.7 63.99  20.0
eGFR rate <60 ml/min/1.73 m2 439 (32.2) 473 (34.5) 151 (45.8)
Serum potassium, mmol/l 4.3  0.4 4.3  0.4 4.30  0.4
Diuretic 1,150 (84.3) 1,176 (85.7) 286 (86.7)
ACE inhibitor 1,068 (78.3) 1,055 (76.8) 266 (80.6)
ARB 261 (19.1) 266 (19.4) 85 (25.8)
ACE inhibitor, ARB, or both 1,282 (94.0) 1,275 (92.9) 316 (95.8)
Beta-blocker 1,181 (86.6) 1,193 (86.9) 286 (86.7)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; eGFR ¼ estimated glomerula3. The efﬁcacy analyses on the primary endpoint (death
from cardiovascular causes or hospitalization for HF)
are performed using a Cox proportional hazards models
including treatment, subgroup, and the treatment-by-
subgroup interaction. Additionally, the corresponding
Kaplan-Meier plots are presented by subgroups.Results
The baseline characteristics of those patients randomized to
placebo or eplerenone in the EMPHASIS-HF study overall,
and in the high-risk subgroups, are presented in Table 1.
There were no striking clinical differences between the
different high-risk subgroups and the overall population,
except those reﬂected by the deﬁning characteristic of the
subgroup.
At the Month 5 visit, after completion of the dose-
adjustment phase 61.3% of patients assigned to receive
eplerenone in the overall study population were taking the
highest dose (50 mg daily); the corresponding proportion in
the overall placebo group was 66.3%. Among the patients in
overall population taking the study drug at the Month 5
visit, the mean  SD doses in the eplerenone and placebo
groups, respectively, were 39.5  13.6 mg and 41.1  12.7
mg. Neither the proportion of patients taking the highest
dose (except for patients with CKD), nor the mean dose
of study drug at the Month 5 visit differed betweenDiabetes
Mellitus eGFR <60 ml/min/1.73 m2
Baseline Systolic
Blood Pressure
 Median
(123 mm Hg)
Eplerenone
Group
(n ¼ 459)
Eplerenone
Group
(n ¼ 439)
Eplerenone
Group
(n ¼ 682)
68.1  7.4 71.1  7.5 68.2  7.6
103 (22.4) 119 (27.1) 148 (21.7)
125.23  17.1 122.23  16.9 110.51  9.1
74.64  10.3 73.19  10.9 69.32  8.7
26.44  4.7 26.39  4.7 25.74  4.8
234 (51.0) 254 (57.9) 394 (57.8)
348 (75.8) 304 (69.2) 374 (54.8)
249 (54.2) 241 (54.9) 352 (51.6)
459 (100.0) 167 (38.0) 211 (30.9)
1.17  0.3 1.44  0.3 1.16  0.3
69.27  22.0 48.59  7.9 68.77  20.7
167 (36.4) 439 (100.0) 246 (36.1)
4.34  0.4 4.36  0.4 4.30  0.4
408 (88.9) 400 (91.1) 592 (86.8)
340 (74.1) 342 (77.9) 551 (80.8)
138 (30.1) 124 (28.3) 166 (24.3)
439 (95.6) 419 (95.4) 649 (95.2)
399 (86.9) 387 (88.2) 587 (86.1)
r ﬁltration rate.
AB
Figure 1 Mean Dose of Study Drug and Discontinuation of Study Drug Due to Adverse Event
(A) Bars for mean dose of study drug (eplerenone vs. placebo) at Month 5 visit in overall study population and in each high-risk subgroup. (B) Bars for discontinuation of study
drug (eplerenone vs. placebo) due to adverse event at Month 5 visit in overall study population and in each high-risk subgroup. DM ¼ diabetes mellitus; eGFR ¼ estimated
glomerular ﬁltration rate; SBP ¼ systolic blood pressure.
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(Fig. 1A).
At the trial cutoff date, in the overall population, the study
drug had been stopped, due to adverse event (at least 1
adverse event leading to drug being stopped), in 188 patients
(13.8%) receiving eplerenone and 222 patients (16.2%)
receiving placebo.
The number of patients with study drug stopped due to
adverse events was evenly distributed within and among the
study high-risk subgroups in patients age 75 years (60 of
330 [18.2%] in eplerenone vs. 62 of 327 [19.0%] in placebo),
in patients with SBP <123 mm Hg (111 of 669 [16.6%] in
eplerenone vs. 122 of 679 [18.0%] in placebo), in patients
with CKD (70 of 436 [16.1%] in eplerenone vs. 105 of 471
[22.3%] in placebo), and in patients with diabetes mellitus
(69 of 457 [15.1%] in eplerenone vs. 72 of 398 [18.1%] inplacebo). Interestingly, in patients with CKD (eGFR <60
ml/min/1.73 m2), there were fewer patients in eplerenone
group who had their treatment stopped due to an adverse
event or due to any other reason than in placebo group
(Fig. 1B).
The principal safety outcomes, change in eGFR and the
primary efﬁcacy outcome in the overall EMPHASIS-HF
study population and in each of the high-risk subgroups,
are summarized in Table 2 and Figure 2.
Safety outcomes. Serum potassium >5.5 and >6.0 mmol/l
occurred preferentially during the ﬁrst 18 months after study
drug (eplerenone and placebo) initiation. After initiation of
the study drug, a serum potassium level >5.5 mmol/l
occurred at a median of 162.5 (range, 4 to 1,032) days in the
eplerenone group compared with 235.0 (range, 7 to 1,008)
days in the placebo group. Serum potassium >6.0 mmol/l
Ta
bl
e
2
P
ri
m
ar
y
O
ut
co
m
e
an
d
M
aj
or
S
af
et
y
Is
su
es
O
ut
co
m
e
E
M
P
H
A
S
IS
-H
F
S
tu
dy
P
op
ul
at
io
n
A
g
e
7
5
yr
s
D
ia
be
te
s
M
el
lit
us
eG
FR
<
6
0
m
l/
m
in
/
1
.7
3
m
2
B
as
el
in
e
S
ys
to
lic
B
lo
od
P
re
ss
ur
e
<
M
ed
ia
n
(1
2
3
m
m
H
g
)
E
pl
er
en
on
e
G
ro
up
(n
¼
1
,3
6
4
)
P
la
ce
bo
G
ro
up
(n
¼
1
,3
7
3
)
E
pl
er
en
on
e
G
ro
up
(n
¼
3
3
0
)
P
la
ce
bo
G
ro
up
(n
¼
3
2
7
)
E
pl
er
en
on
e
G
ro
up
(n
¼
4
5
9
)
P
la
ce
bo
G
ro
up
(n
¼
4
0
0
)
E
pl
er
en
on
e
G
ro
up
(n
¼
4
3
9
)
P
la
ce
bo
G
ro
up
(n
¼
4
7
3
)
E
pl
er
en
on
e
G
ro
up
(n
¼
6
6
9
)
P
la
ce
bo
G
ro
up
(n
¼
6
8
3
)
H
os
pi
ta
liz
at
io
n
fo
r
he
ar
t
fa
ilu
re
or
de
at
h
fo
r
ca
rd
io
va
sc
ul
ar
2
4
9
(1
8
.3
%
)
3
5
6
(2
5
.9
%
)y
7
8
(2
3
.6
%
)
1
0
7
(3
2
.7
%
)y
9
9
(2
1
.7
%
)
1
4
1
(3
5
.2
%
)z
1
0
7
(2
4
.4
%
)
1
6
3
(3
4
.5
%
)z
1
3
8
(2
0
.6
%
)
2
0
1
(2
9
.4
%
)z
Se
ru
m
K
þ
>
5
.5
m
m
ol
/l
1
5
8
/1
,3
3
6
(1
1
.8
%
)
9
6
/1
,3
4
0
(7
.2
%
)z
4
0
/3
2
2
(1
2
.4
%
)
2
1
/3
1
8
(6
.6
%
)*
6
3
/4
4
7
(1
4
.1
%
)
3
3
/3
8
7
(8
.5
%
)y
7
0
/4
2
2
(1
6
.6
%
)
4
3
/4
6
1
(9
.3
%
)y
7
2
/6
5
8
(1
0
.9
%
)
4
8
/6
6
0
(7
.3
%
)*
Se
ru
m
K
þ
>
6
.0
m
m
ol
/l
3
3
/1
,3
3
6
(2
.5
%
)
2
5
/1
,3
4
0
(1
.9
%
)
7
/3
2
2
(2
.2
%
)
4
/3
1
8
(1
.3
%
)
1
7
/4
4
7
(3
.8
%
)
8
/3
8
7
(2
.1
%
)
8
/4
2
2
(1
.9
%
)
1
5
/4
6
1
(3
.3
%
)
1
4
/6
5
8
(2
.1
%
)
1
6
/6
6
0
(2
.4
%
)
C
ha
ng
e
in
eG
FR
fr
om
ba
se
lin
e
to
ﬁ
na
lv
is
it
(M
ea
n
(S
D
)
3
.1
8
(1
8
.4
)
1
.2
9
(1
8
.2
)*
5
.2
9
(1
7
.6
)
4
.0
7
(1
5
.4
)
4
.9
4
(1
7
.4
)
2
.9
3
(1
8
.9
)
2
.0
4
(1
7
.0
)
4
.1
5
(1
4
.9
)
1
.3
1
(1
7
.3
)
0
.0
7
(1
7
.5
)
D
iff
er
en
ce
be
tw
ee
n
ep
le
re
no
ne
an
d
pl
ac
eb
o
gr
ou
ps
w
ith
in
di
ff
er
en
t
su
bg
ro
up
s:
*p

0
.0
5
;y
p

0
.0
1
;
zp

0
.0
0
0
1
.
A
bb
re
vi
at
io
ns
as
in
Ta
bl
e
1
.
JACC Vol. 62, No. 17, 2013 Eschalier et al.
October 22, 2013:1585–93 Eplerenone in High-Risk Patients
1589occurred at 276 (range, 4 to 987) days in the eplerenone
group and 235.0 (range, 7 to 596) days in the placebo group.
Of 150 patients receiving eplerenone who had potassium
>5.0 mmol/l at Week 4, 141 (94.0%) did not have their
study drug dose increased, as per protocol. For comparison,
of 94 patients receiving placebo who had potassium >5.0
mmol/l at Week 4, and 83 (88.3%) did not have their study
drug dose increased.
Patients ‡75 years of age. There was an increase in the
proportion of older patients with a follow-up potassium
>5.5 mmol/l in those treated with eplerenone compared
with placebo, 40 (12.4) versus 21 (6.6), p ¼ 0.02, but there
was no difference in the proportion with a potassium >6.0
mmol/l, 7 (2.2) versus 4 (1.3), p ¼ 0.55. There was no
increase in any other safety outcome with eplerenone.
However, the reduction in SBP between baseline and the
ﬁnal visit was greater in the eplerenone group, –4.75 (18.8)
versus –0.70 (16.5) mm Hg, p ¼ 0.03, compared with the
placebo group.
Furthermore, age (<75 vs. 75 years) did not modify the
effect of eplerenone on the risk of severe hyperkalemia
(interaction p ¼ 0.64) or of change in eGFR from baseline
to ﬁnal visit (interaction p ¼ 0.5071).
Patients with diabetes mellitus. There was an increase in
the incidence of potassium >5.5 mmol/l with eplerenone in
patients with diabetes, 63 (14.1) versus 33 (8.5) on placebo,
p ¼ 0.01. However, none of the other safety outcomes were
increased in the eplerenone group, especially in the
proportion with a serum potassium >6.0 mmol/l, 17 (3.8)
versus 8 (2.1) on placebo, p ¼ 0.16, and no more patients
discontinued eplerenone for hyperkalemia in diabetes versus
no-diabetes patients (interaction p ¼ 0.12).
Patients with CKD (i.e., an eGFR <60 ml/min/1.73 m2).
There was an increase in the incidence of potassium >5.5
mmol/l with eplerenone in patients with CKD, 70 (16.6)
versus 43 (9.3) on placebo, p ¼ 0.002. There was no increase
in any other safety outcome with eplerenone, including in the
proportion with a serum potassium >6.0 mmol/l, 8 (1.9)
versus 15 (3.3) on placebo, p ¼ 0.29.
Furthermore, there was actually a decrease in incident
potassium >6.0 mmol/l, 8 (1.9) versus 25 (2.74), p ¼ 0.01,
but an increase in hyperkalemia leading to treatment
discontinuation, 5 (1.15) versus 10 (1.08), p ¼ 0.01, in
eplerenone patients with CKD compared with patients
without CKD.
Patients with below median SBP (<123 mm Hg). There
was an increase in the incidence of potassium >5.5 mmol/l
in patients with a SBP <123 mm Hg, 72 (10.9) versus 48
(7.3) on placebo, p¼ 0.02. There was no increase in any other
safety outcome with eplerenone, especially in the proportion
with a serum potassium>6.0 mmol/l, 14 (2.1) versus 16 (2.4)
on placebo, p ¼ 0.85. Interestingly, there was no increase in
the incidence of serum potassium >5.5 nor >6.0 mmol/l
with eplerenone in patients in the lowest quartile of baseline
SBP (<110 mm Hg) and in patients with SBP between
lowest quartile and median (between 110 and 123 mm Hg).
A B
C D
Figure 2 Kaplan-Meier Curves for the Primary Composite Endpoint
The hazard ratios for eplerenone versus placebo are shown for the primary composite endpoint (hospitalization for HF or death from cardiovascular causes), according to high-
risk subgroups (A ¼75 years old; B¼ history of diabetes; C¼ estimated glomerular ﬁltration rate<60 ml/min/1.73 m2; D ¼ systolic blood pressure<median [123 mm Hg]).
CI ¼ conﬁdence interval.
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eplerenone in the EMPHASIS-HF study was 2 mm Hg
overall. In patients with a SBP below the median of 123
mm Hg, SBP pressure increased on average by 4.96 (16.0)
mm Hg in the eplerenone group versus 5.98 (16.2) mm Hg
in the placebo group (p ¼ 0.19). In patients with
SBP  median (123 mm Hg) there was a signiﬁcantly
higher decrease in SBP in the eplerenone group as compared
with the placebo group, –9.6 (16.8) mm Hg versus –6.27
(15.9) mm Hg, p < 0.001.
Furthermore, SBP (<123 vs. 123 mm Hg) did not
modify the effect of eplerenone on the risk of severe hyper-
kalemia (p ¼ 0.10) or of change in eGFR from baseline to
ﬁnal visit (p ¼ 0.66).
Primary efﬁcacy outcome. Eplerenone was effective
at reducing the risk of cardiovascular death or HFhospitalization in the high-risk subgroups, which is consis-
tent with result in the overall, the EMPHASIS-HF study
population (hazard ratio [HR]: 0.63; 95% conﬁdence interval
[CI]: 0.54 to 0.74; p < 0.001).
Correspondingly, the HR for the primary outcome in
the eplerenone group as compared with the placebo group
was 0.66 (95% CI: 0.54 to 0.80; p < 0.0001) in patients
<75 years of age, 0.72 (95% CI: 0.58 to 0.88; p ¼ 0.002)
in patients without diabetes, 0.69 (95% CI: 0.56 to 0.86;
p ¼ 0.0008) in patients without CKD, and 0.68 (95% CI:
0.53 to 0.87; p ¼ 0.002) in patients with SBP  median. All
interaction tests were not signiﬁcant.
The HR for the primary outcome in the eplerenone group
as compared with the placebo group was 0.66 (95% CI: 0.49
to 0.88; p ¼ 0.005) in patients 75 years of age, 0.54 (95%
CI: 0.42 to 0.70; p < 0.0001) in patients with diabetes,
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CKD, and 0.63 (95% CI: 0.51, 0.79; p < 0.0001) in patients
with SBP < median (123 mm Hg) (Fig. 2).
Moreover the HR for the primary outcome (hospitaliza-
tion for HF and/or cardiovascular death) in the eplerenone
group as compared with the placebo group was 0.63
(95% CI: 0.44 to 0.89; p ¼ 0.009) in patients in the lowest
quartile of baseline SBP<25 percentile (<110 mmHg), and
0.64 (95% CI: 0.48 to 0.84; p ¼ 0.001) in patients with SBP
between the lowest and median (110 and 123 mm Hg).
Discussion
The present ﬁndings show that eplerenone, started at a dose
of 25 mg and carefully up-titrated to 50 mg (mean dose 40
mg) as tolerated, has a favorable beneﬁt-risk proﬁle in care-
fully selected and monitored patients, even if at increased risk
of renal dysfunction, hyperkalemia and hypotension because
of advanced age, diabetes, CKD, or low SBP. Speciﬁcally, the
beneﬁt of reduced incidence of cardiovascular death or HF
hospitalization was preserved in all the high-risk subgroups
studied without an increase in the risk of serious hyperkalemia
and worsening renal function in any subgroup.
Older patients (‡75 years of age). Aldosterone levels
decrease with age (7). However, aldosterone is not the only
natural ligand of MR. Cortisol is a very potent agonist of
MRs, but in physiological conditions, the enzyme 11bHSD2
converts cortisol to cortisone, which does not activate theMR
(8). Importantly, however, there is a decrease in the expres-
sion of this enzyme with age. Thus in the elderly, cortisol may
be more active on MR in the vascular wall, renal tubule, and
myocardium. There is also an increase in the expression of the
MR with age in the vascular wall (9), which, in conjunction
with the decrease in expression of 11bHSD2, suggests that
MR signaling may be as or more important in the elderly than
in younger patients.
Clinicians may also be concerned about the safety of
adding aMRA to an ACE-I or ARB and a BB in the elderly.
It was therefore of interest to note that both the mean dose
and the percentage of patients attaining the highest dose of
eplerenone at the Month 5 visit was the same in older
patients as in the overall EMPHASIS-HF study population.
Similarly, the frequencies of the pre-speciﬁed safety outcomes
were generally similar in older patients and in patients <75
years of age.
Diabetes mellitus. Diabetes mellitus is a major risk factor
for the development of hyperkalemia (10) and renal failure.
One postulated explanation for the increased risk of hyper-
kalemia in diabetes is hyporeninemic hypoaldosteronism.
However, risks were not increased in diabetes (except
modest hyperkalemia) suggesting that hyporeninemic
hypoaldosteronism may be actually not quite common in
diabetes. Excess hyperkalemia might just be due to the
associated CKD.
Although the present data show that eplerenone is simi-
larly beneﬁcial in patients with diabetes than in thosewithout, Eplerenone does not reduce new onset of diabetes
in this population (11).
It is therefore reassuring that eplerenone appeared to be
well tolerated and safe in the selected and carefully moni-
tored patients with diabetes in EMPHASIS-HF (38% of
which had concomitant CKD).
Chronic kidney disease. Aldosterone-induced kidney
injury is likely to be multifactorial, including its effect on
systemic blood pressure, renal vasculature, local inﬂamma-
tion, and ﬁbrosis (12). In addition to the traditional
pathway, in renal tubular epithelial cells, activation of MR in
nonepithelial tissues has been shown to cause hypertrophy
and ﬁbrosis (13).
Patients with HF-REF and concomitant CKD
(eGFR <60 ml/min/1.73 m2) are at increased cardiovascular
risk compared to those with preserved renal function, but
they are less likely to be treated with renin-angiotensin-
aldosterone system blockers or to receive the target dose of
these agents. However, several studies and reviews high-
lighted the beneﬁt of the addition of MRAs to ACE-I and/
or ARB therapy in patients with proteinuric kidney disease
to signiﬁcantly reduce proteinuria, without causing signiﬁ-
cant hyperkalemia or worsening renal function (14,15).
Furthermore, Vardeny et al. recently showed in a substudy of
the RALES study that the absolute beneﬁt of spironolactone
was greatest in patients with reduced eGFR (eGFR <60 ml/
min/1.73 m2) (16).
It was therefore especially reassuring that while there was
an increase in the frequency of mild hyperkalemia (serum
potassium >5.5 mmol/l) in patients randomized to epler-
enone, there was also no signiﬁcant increase in the frequency
of serious hyperkalemia or WRF.
It is our view, therefore, that patients with HF-REF and
concomitant CKD, meeting the inclusion and exclusion
criteria of the EMPHASIS-HF study, should cautiously be
given a trial of eplerenone beginning at a dose of 25 mg/day,
with serial monitoring of serum potassium in an attempt to
reduce the particularly high mortality and morbidity in
these patients. It must, however, be emphasized that
although this analysis was performed for patients with
eGFR <60 ml/min/1.73 m2, those with an eGFR <30 ml/
min/1.73 m2 and those with a baseline serum potassium
>5.0 mmol/l were excluded from the study. Furthermore,
those with eGFR 30 to 49 ml/min/1.73 m2 had a different
and more cautious dosing regimen (eplerenone was started
at a dose of 25 mg every other day and increased to 25 mg
daily 4 weeks, provided the serum potassium was no more
than 5.0 mmol/l).
SBP below median (<123 mm Hg). Hypotension is a
particular concern in patients with HF-REF who often have
an intrinsically low SBP and usually an indication for 3 or
more BP-lowering drugs (17). These concerns are greatest in
the elderly who are at risk of orthostatic hypotension leading
to falls and loss of consciousness.
As in the other pre-speciﬁed high-risk subgroups in this
analysis the use of eplerenone did not result in any
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or WRF. Interestingly there was no clinically signiﬁcant
decrease of SBP in those with SBP < median.
This experience with eplerenone 25 to 50 mg/daily in the
various high-risk subgroups reported here is in contrast to
that reported over the last several years from many centers
who noted frequent intolerance of MRAs, in part related to
a high incidence of hyperkalemia, acute renal failure, or
both. For example after the RALES study (1), Juurlink et al.
(18) noted an increased incidence of hospitalization for
hyperkalemia in Ontario in patients with HF treated with
spironolactone (patients were on average 13 years older than
in the RALES study). More recently the TIME-CHF (the
Trial of Intensiﬁed vs Standard Medical Therapy in Elderly
Patients With Congestive Heart Failure randomized trial)
investigators (19) found that the use of spironolactone
>25 mg/day in patients >60 years of age was associated
with a more than 25% incidence of mild hyperkalemia
(>5.5 mmol/l). A recent study from the Cleveland Clinic,
evaluating the use of MRAs in patients admitted with HF
after the results of EMPHASIS-HF (2), noted a high
incidence (40%) of MRA (spironolactone in 90% of cases)
discontinuation during hospitalization (20).
One explanation for the high incidence of hyperkalemia
and/or WRF, as well as intolerance associated with the use
of a MRA, in these patients is that many clinicians have
used spironolactone in the dosing regimen used in RALES
(12.5 to 50 mg/day) in patients with HF and mild symp-
toms such as those in the EMPHASIS-HF study (19,21).
These doses may not be associated to the same risk/beneﬁt
than observed with eplerenone 25 to 50 mg in the
EMPHASIS-HF study. Furthermore all these studies
included both patients with HF with preserved ejection
fraction, in whom MRAs were not recommended, as well as
those with HF-REF. Importantly patients included in
studies cited above were on average older, with more severe
CKD (patients with eGFR <30 ml/min/1.73 m2 were
included in the TIME-CHF study) and received higher
MRA doses than in the RALES or EMPHASIS-HF
studies (22). Finally, patients may have also taken nonste-
roidal anti-inﬂammatory agents, other potassium-sparing
diuretics, and potassium supplements in these studies,
drugs that increase the risk of developing serious hyper-
kalemia and/or WRF. Those patients were excluded from
the EMPHASIS-HF study. Furthermore, patients included
in the EMPHASIS-HF study, as in other trials cited
previously, had to be on optimal ACE-I/ARB therapy
before enrollment, which may have selected out a population
less likely to have hyperkalemia or WRF secondary to MRA,
as compared with unselected patients reported in observa-
tional registries. It is appropriate to emphasize that our
conclusions are limited to the EMPHASIS-HF study type
of patients and may not apply to the patients at the highest
risk for complications who were excluded from the study.
The subsets evaluated in the current analysis represent high-
risk subgroups, which were not excluded by the entry criteria.Importantly, surveillances of serum potassium and renal
function were probably more closely made in patients
included in the EMPHASIS-HF study than in “real-life”
patients.
Study limitations. Based on the very low incidence rates of
severe hyperkalemia (K >6.0 mmol/l) and the sample sizes,
the comparisons within subgroups are underpowered, and
therefore, type II error cannot be excluded and the lack of
statistical signiﬁcance should not be portrayed as categorical
proof that patients on eplerenone have no difference in risk
(either greater or smaller) than placebo patients. However, 2
subgroups showed a greater percentage for eplerenone and 2
showed a greater percentage for placebo.
Conclusions
The excellent beneﬁt-to-risk ratio of eplerenone in the
subgroups in this analysis at high risk for developing hyper-
kalemia and/or worsening renal function with an excellent
safety and tolerance combined with a substantial reduction of
the combined endpoint of cardiovascular mortality and hospi-
talization for HF, presents compelling evidence for its use in all
patients with HF-REF meeting the inclusion and exclusion
criteria of the EMPHASIS-HF study. Even so, serum potas-
sium and renal function have to be carefully monitored in
these patients strictly selected to beneﬁt from MRAs.
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